Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 14/20 | 0.86 |
| ▸ | RET | P07949 | 4/20 | 0.80 |
| ▸ | KDR | P35968 | 6/20 | 0.69 |
| ▸ | ABL1 | P00519 | 3/20 | 0.69 |
| ▸ | EPHA2 | P29317 | 3/20 | 0.69 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.69 |
| ▸ | MAP3K20 | Q9NYL2 | 3/20 | 0.69 |
| ▸ | SRC | P12931 | 3/20 | 0.69 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.69 |
| ▸ | PLK4 | O00444 | 2/20 | 0.69 |
| ▸ | AURKA | O14965 | 2/20 | 0.69 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.69 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.69 |
| ▸ | LCK | P06239 | 2/20 | 0.69 |
| ▸ | FYN | P06241 | 2/20 | 0.69 |
| ▸ | LYN | P07948 | 2/20 | 0.69 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.69 |
| ▸ | AXL | P30530 | 2/20 | 0.69 |
| ▸ | FRK | P42685 | 2/20 | 0.69 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL549001 | 0.92 | RAF1 (1.00) | RAF1RETKDRABL1EPHA2 | |
| SCHEMBL13946049 | 0.91 | RAF1 (0.71) | RAF1RETKDRABL1EPHA2 | |
| SCHEMBL1506380 | 0.89 | RET (1.00) | RAF1RETKDRABL1EPHA2 | |
| SCHEMBL5082237 | 0.87 | RAF1 (0.83) | RAF1RETKDRABL1EPHA2 | |
| SCHEMBL1506452 | 0.87 | RAF1 (0.82) | RAF1RETKDRABL1EPHA2 | |
| SCHEMBL1506322 | 0.86 | RAF1 (0.78) | RAF1RETKDRABL1EPHA2 | |
| SCHEMBL14453669 | 0.86 | KDR (0.73) | RAF1RETKDRABL1EPHA2 | |
| SCHEMBL171259 | 0.84 | RAF1 (0.80) | RAF1RETKDRABL1EPHA2 | |
| SCHEMBL1506316 | 0.84 | RAF1 (0.66) | RAF1RETKDRABL1EPHA2 | |
| SCHEMBL4466716 | 0.83 | RAF1 (0.65) | RAF1RETKDRABL1EPHA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2298311-B1 | w-Carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors | BAYER HEALTHCARE LLC (US) | 2012-05-09 | — | — | EP | claimed |
| EP-1158985-B1 | OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS | BAYER HEALTHCARE LLC (US) | 2011-12-28 | — | — | EP | claimed |
| EP-2298311-A1 | w-Carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors | Bayer Healthcare Llc (US) | 2011-03-23 | — | — | EP | claimed |
| EP-1158985-A4 | OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS | BAYER PHARMACEUTICALS CORP (US) | 2008-03-12 | — | — | EP | claimed |
| JP-3845792-B2 | — | — | 2006-11-15 | — | — | JP | claimed |
| EP-1690853-A1 | W-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | Bayer Pharmaceuticals Corporation (US) | 2006-08-16 | — | — | EP | claimed |
| EP-1140840-B1 | -G(V)-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | BAYER PHARMACEUTICALS CORP (US) | 2006-03-22 | — | — | EP | claimed |
| US-20030207872-A1 | OMEGA-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | BAYER CORPORATION | 2003-11-06 | — | — | US | claimed |
| US-20030181442-A1 | Carbamides such as N-(3-tert-butylphenyl)-N'-(4-(3-(N-methyl-carbamoyl)phenoxy)phenyl urea, used as enzyme inhibitors and as anticarcinogenic agents | BAYER CORPORATION | 2003-09-25 | — | — | US | claimed |
| JP-2003526613-A | — | — | 2003-09-09 | — | — | JP | claimed |
| US-20020042517-A1 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER CORPORATION | 2002-04-11 | — | — | US | claimed |
| EP-1158985-A1 | OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS | Bayer Corporation (US) | 2001-12-05 | — | — | EP | claimed |
| US-20010034447-A1 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC | 2001-10-25 | — | — | US | claimed |
| EP-1140840-A1 | -G(V)-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | Bayer Corporation (US) | 2001-10-10 | — | — | EP | claimed |
| US-20010027202-A1 | Omega-carboxyaryl substituted disphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC | 2001-10-04 | — | — | US | claimed |
| US-20010016659-A1 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC | 2001-08-23 | — | — | US | claimed |
| US-20010011135-A1 | Omega-carboxyaryl subsituted diphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC | 2001-08-02 | — | — | US | claimed |
| US-20010011136-A1 | omega-carboxyyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC | 2001-08-02 | — | — | US | claimed |
| WO-2000041698-A1 | φ-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS | BAYER CORPORATION (US) | 2000-07-20 | — | — | WO | claimed |
| WO-2000042012-A1 | φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | BAYER CORPORATION (US) | 2000-07-20 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030181442-A1 | Carbamides such as N-(3-tert-butylphenyl)-N'-(4-(3-(N-methyl-carbamoyl)phenoxy)phenyl urea, used as enzyme inhibitors and as anticarcinogenic agents | NRAS, BRAF, RAF1 | RAF1 3/4885RET 83/4885KDR 3100/4885 |
| US-20010011135-A1 | Omega-carboxyaryl subsituted diphenyl ureas as raf kinase inhibitors | BRAF, RAF1, ARAF | RAF1 2/4885RET 128/4885KDR 611/4885 |
| US-20010011136-A1 | omega-carboxyyaryl substituted diphenyl ureas as raf kinase inhibitors | BRAF, ARAF, RAF1 | RAF1 3/4885RET 170/4885KDR 624/4885 |
| US-20010034447-A1 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BRAF, RAF1, ARAF | RAF1 2/4885RET 182/4885KDR 567/4885 |
| US-20010016659-A1 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BRAF, RAF1, ARAF | RAF1 2/4885RET 182/4885KDR 567/4885 |
| US-20030207872-A1 | OMEGA-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | RAF1 2/4885RET 182/4885KDR 567/4885 |
| US-20010027202-A1 | Omega-carboxyaryl substituted disphenyl ureas as raf kinase inhibitors | BRAF, NRAS, ARAF | RAF1 4/4885RET 70/4885KDR 487/4885 |
| US-20020042517-A1 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BRAF, RAF1, ARAF | RAF1 2/4885RET 182/4885KDR 567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.